How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs

China has set a goal to become a global leader in biomedicine by 2030, aiming to capture at least 25% of the world's first-in-class drugs market. This ambitious target is part of a new five-year plan that focuses on key technological breakthroughs. If achieved, China would firmly rank at the global forefront in biopharmaceutical research and development, significantly increasing its core competitiveness and international influence. This could have a major impact on the global pharmaceutical industry, potentially shifting the balance of power and influencing trade in this sector.

Why it matters

China's regulator is signalling a strong push for biomedicine innovation. That could lift investor sentiment and pull in foreign capital for Chinese biotech companies.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to South China Morning Post. For information only — not financial advice.